<DOC>
	<DOCNO>NCT02361255</DOCNO>
	<brief_summary>Parkinson 's disease ( PD ) Drug-induced Parkinsonism ( DIP ) clinically indistinguishable DIP sometimes represent `` unmasking underlying PD . The objective study determine relationship underlie Parkinson 's disease ( PD ) incidence clinical outcome DIP use non-motor assessment marker nigrostriatal degeneration . Research Design : This nested case-control design investigate risk factor associate development DIP persistent Parkinsonism antipsychotic ( AP ) withdrawal ( potential clinical marker underlie PD ) . Target enrollment 45 subject . Methodology : We examine objective olfactory function ( via objective olfactory test ) , non-motor symptom PD ( via standardize validated questionnaire ) , motor finding ( via clinical exam quantitative gait analysis ) : 1 ) DIP patient ( 30 subject ) compare AP-treated patient without Parkinsonism ( 15 subject ) 2 ) patient persistent Parkinsonism compare whose symptom resolve DIP cohort follow prospectively change AP treatment . Additionally , patient perform clinically , evaluate dopamine transporter SPECT imaging ( DaTI ) marker nigrostriatal integrity examine ability qualitative semi-quantitative analysis distinguish pharmacologic degenerative Parkinsonism . We also measure serum uric acid Apolipoprotein A1 , two putative biomarkers early PD , examine relationship clinical radiologic status .</brief_summary>
	<brief_title>Degenerative Nigrostriatal Dysfunction Drug-induced Parkinsonism</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Parkinson Disease , Secondary</mesh_term>
	<criteria>antipsychotic treat patient without parkinsonism parkinson 's disease , dementia</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>